A phase 2/3 double-blind trial randomised 643 Indian infants to a dose-sparing adjuvanted inactivated poliovirus vaccine or to standard IPV. Seroconversion for type 1 was 94.7% with the dose-sparing vaccine and 92.8% with standard IPV, a difference of 1.9% with an interval from -2.1 to 5.8. Type 2 was 96.3% against 97.9% and type 3 was 97.3% against 99.0%, both differences small and their intervals crossing zero.
Solicited reactions — tenderness, redness, swelling, fever — were very common in both arms, and no causally related serious adverse events occurred.
The significance is supply rather than immunology. Inactivated polio vaccine has been the constraint on eradication programmes for years, and an adjuvanted formulation that reaches the same seroconversion with less antigen stretches the same manufacturing capacity further. For an Indian immunisation programme this is a procurement question that becomes a coverage question.
- Immunogenicity, not efficacy — seroconversion is the accepted surrogate here
- All three serotypes met non-inferiority against standard IPV
- Reactogenicity was similar; adjuvanted does not mean more reactions here
- The value is antigen sparing and therefore supply, not a better vaccine
- Conducted in Indian infants, so the population is the one that would use it
The statistics, in plain English
Non-inferiority asks whether the new vaccine is not meaningfully worse, within a margin agreed in advance — not whether it is better. Type 2 and type 3 both came out slightly lower (-1.6%) with intervals crossing zero, which passes that test. Reading those as evidence the new vaccine is worse would be over-interpreting a difference the trial was not designed to detect.
Read the rest in the app
You have read your two free briefings this month. The app carries all 27 specialties, every morning, free — and this finding is waiting in it.
Scan to keep reading on your phone. No account needed to start.
Tomorrow morning, before your first patient
One edition a day for infectious diseases, written by the desk, every claim tied to its paper. Six minutes.
Get the app — free